GLP-1R behavior may differ across tissues, assay systems, and experimental conditions
Given the considerable continued growth expected in the GLP-1 pipeline, Primes team of clinical experts actively monitors this emerging landscape
Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes. New England Journal of Medicine , 391(2), 109121
Studies in adults without diabetes show that GLP-1 drugs reduce appetite and calorie intake, which helps explain why weight loss happens
Early disease onset is generally associated with faster progression and higher mortality
Juntos, eles servem como um modelo para o estudo da pulsatilidade do GH induzida por peptdeos, da interao entre receptores e da regulao hipotalmico-hipofisria em sistemas experimentais controlados